✦ LIBER ✦

Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin

✍ Scribed by Láng, István; Köhne, Claus-Henning; Folprecht, Gunnar; Rougier, Philippe; Curran, Desmond; Hitre, Erika; Sartorius, Ute; Griebsch, Ingolf; Van Cutsem, Eric

Book ID: 122016487
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 325 KB
Volume: 49
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2012.08.023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First-line panitumumab plus irinotecan/5

First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer

✍ Claus-Henning Köhne; Ralf Hofheinz; Laurent Mineur; Henry Letocha; Richard Greil 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 584 KB

Cost-Effectiveness of Cetuximab, Cetuxim

Cost-Effectiveness of Cetuximab, Cetuximab Plus Irinotecan, and Panitumumab for Third and Further Lines of Treatment for KRAS Wild-Type Patients with Metastatic Colorectal Cancer

✍ Hoyle, Martin; Peters, Jaime; Crathorne, Louise; Jones-Hughes, Tracey; Cooper, C 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 378 KB

Biweekly cetuximab plus FOLFIRI/irinotec

Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population

✍ Chen, Ye; Cao, Dan; Bi, Feng; Li, Qiu; Qiu, Meng 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 222 KB

Cetuximab Plus Irinotecan, Fluorouracil,

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

✍ Van Cutsem, E.; Kohne, C.-H.; Lang, I.; Folprecht, G.; Nowacki, M. P.; Cascinu, 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 219 KB

Fluorouracil, Leucovorin, and Oxaliplati

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

✍ Bokemeyer, C.; Bondarenko, I.; Makhson, A.; Hartmann, J. T.; Aparicio, J.; de Br 📂 Article 📅 2009 🏛 American Society of Clinical Oncology 🌐 English ⚖ 201 KB

Fluorouracil, Leucovorin, and Oxaliplati

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

✍ Bokemeyer, C.; Bondarenko, I.; Makhson, A.; Hartmann, J. T.; Aparicio, J.; de Br 📂 Article 📅 2009 🏛 American Society of Clinical Oncology 🌐 English ⚖ 201 KB

## Purpose This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior to that of FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer. The influence of KRAS mutation sta